Skip to main content

Table 1 Clinical characteristics of study participants (ELISA)

From: Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjögren’s syndrome

 

Healthy

Non-severe

Severe

p-value

n

49

42

54

-

Age (years)

50.6±8.3

54.1±17.8

58.3±15.3

0.26

Sex (% female)

100%

100%

100%

NA

Duration from onset (years)

-

8.1±10.4a

12.4±13.8b

0.22

Duration from diagnosis (years)

-

5.7±7.4c

8.7±7.7d

0.092

BMI

-

25.7±4.3e

25.5±5.5f

0.59

Stimulated salivary flow rate

-

7.0±3.3 ml/5 min

1.8±0.8 ml/5 min

< 2.2 × 10-16

Schirmer right (mm/5 min)

-

8.1±10.5g

6.3±9.0d

0.49

Schirmer left (mm/5 min)

-

9.4±11.3g

6.9±9.6d

0.36

Anti-SSA

-

27/73.0%h

35/74.5%i

0.88

Anti-SSB

-

8/21.6%h

14/29.8%i

0.40

Seropositive (SSA and/or SSB)

-

27/73.0%h

35/74.5%i

0.88

cDMARD

-

11/32.4%e

10/24.4%j

0.21

bDMARD (anti-TNF)

-

0k

0k

NA

Glucocorticoid

-

4/11.8%e

2/5.0%l

0.30

Cyclosporine eye drops

-

6/27.3%m

725.9%n

0.93

Oral pilocarpine

-

3/14.3%o

4/16%p

0.89

Natural tears

-

6/25%q

10/38.5%r

0.32

Angina pectoris

-

1r

0l

0.23

Autoimmune gastritis

-

0r

1s

0.43

Autoimmune thyroid disease

-

1j

4t

0.27

Proteinuria

-

0p

3u

0.16

Hematuria

-

0p

1g

0.42

Gynaecologic manifestation

-

1p

2s

0.85

Non-specific interstitial pneumonia

-

0q

1h

0.44

Fibromyalgia

-

0q

2s

0.27

Anemia

-

2p

3s

0.98

Leukopenia

-

1p

3s

0.57

Neutropenia

-

1p

2s

0.85

Thrombocytopenia

-

0p

1s

0.44

Cancer

-

1p

1u

0.78

Sclerosing cholangitis

-

0p

1u

0.44

Psoriasis

-

1j

1t

0.88

Other autoimmune diseases

-

1j

1t

0.88

  1. Values for continuous variables are presented in mean ± SD. Mann-Whitney U test was used in the comparison between non-severe and severe patients
  2. an=20, bn=19, cn=36, dn=43, en=34, fn=42, gn=35, hn=37, in=47, jn=41, kn=17, ln=40, mn=22, nn=27, on=21, pn=25, qn=24, rn=26, sn=39, tn=52, un=38